EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts



RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts



Journal of Leukocyte Biology 86(3): 505-512



The RAGE binds multiple ligand families linked to hyperglycemia, aging, inflammation, neurodegeneration, and cancer. Activation of RAGE by its ligands stimulates diverse signaling cascades. The recent observation that the cytoplasmic domain of RAGE interacts with diaphanous or mDia-1 links RAGE signal transduction to cellular migration and activation of the Rho GTPases, cdc42 and rac-1. Pharmacological blockade of RAGE or genetic deletion of RAGE imparts significant protection in murine models of diabetes, inflammatory conditions, Alzheimer's disease, and tumors. Intriguingly, soluble forms of RAGE, including the splice variant-derived esRAGE, circulate in human plasma. Studies in human subjects suggest that sRAGE levels may be modulated by the diseases impacted by RAGE and its ligands. Thus, in addition to being a potential therapeutic target in chronic disease, monitoring of plasma sRAGE levels may provide a novel biomarker platform for tracking chronic inflammatory diseases, their severity, and response to therapeutic intervention.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333040

Download citation: RISBibTeXText

PMID: 19477910

DOI: 10.1189/jlb.0409230



Related references

Receptor for advanced glycation end products (RAGE): novel biomarker and therapeutic target for atrial fibrillation. International Journal of Cardiology 168(5): 4802-4804, 2014

AKT1 gene amplification as a biomarker of treatment response in ovarian cancer: mounting evidence of a therapeutic target. Gynecologic Oncology 135(3): 409-410, 2015

RAGE A New Target for MMP-9 in the Regulation of Inflammatory Response in the Lung During Oxidative Stress. FASEB Journal 18(4-5): Abst 774 18, 2004

The AGEs-RAGE axis and nonalcoholic steatohepatitis: the evidence mounts. Journal of Gastroenterology 45(7): 782-783, 2010

Antibody response to BK polyomavirus as a prognostic biomarker and potential therapeutic target in prostate cancer. Oncotarget 6(8): 6459-6469, 2016

Serum caveolin-1, a biomarker of drug response and therapeutic target in prostate cancer models. Cancer Biology & Therapy 14(2): 117-126, 2013

Evidence that the preterm fetus mounts a more intense systemic inflammatory response than the term fetus in intra-amniotic infection. American Journal of Obstetrics & Gynecology 187(6 Supplement): S128, December, 2002

FAS Death Receptor: A Breast Cancer Subtype-Specific Radiation Response Biomarker and Potential Therapeutic Target. Radiation Research 184(5): 456-469, 2016

Receptor for advanced glycation end products (RAGE), inflammatory ligand EN-RAGE and soluble RAGE (sRAGE) in subjects with Takayasu's arteritis. International Journal of Cardiology 168(1): 532-534, 2014

RAGE in inflammation: a new therapeutic target?. Current Opinion in Investigational Drugs 7(11): 985-991, 2006

Is RAGE still a therapeutic target for Alzheimer's disease?. Future Medicinal Chemistry 4(7): 915-925, 2012

The IL-12/23/STAT Axis as a Therapeutic Target in Inflammatory Bowel Disease: Mechanisms and Evidence in Man. Digestive Diseases 33 Suppl 1(): 113-119, 2015

GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential. Expert Review of Clinical Immunology 11(4): 457-465, 2015

Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochemical Pharmacology 79(10): 1379-1386, 2010

Chemokines and the inflammatory response following cardiopulmonary bypass--a new target for therapeutic intervention?--A review. Paediatric Anaesthesia 13(8): 655-661, 2003